Home › Metastatic Cancer › Vermont › Burlington
Metastatic Cancer clinical trials in Burlington, VT
4 studies for Metastatic Cancer are looking for participants at sites in and around Burlington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RecruitingPhase 3
- The University of Vermont Medical Center Inc., Burlington
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- The University of Vermont Medical Center Inc., Burlington
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RecruitingPhase 1
- University of Vermont Medical Center, Burlington
Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial
RecruitingPhase 2
- University of Vermont Medical Center, Burlington
Metastatic Cancer trials in other cities
- Houston, TX104 studies
- New York City, NY93 studies
- Nashville, TN70 studies
- Boston, MA63 studies
- Los Angeles, CA57 studies
- St. Louis, MO54 studies
- Arlington, VA53 studies
- Philadelphia, PA46 studies
- Chicago, IL45 studies
- San Antonio, TX44 studies
- Washington, DC43 studies
- Dallas, TX42 studies
Other studies in Burlington
- Heart Failure8 studies
- Acute Myeloid Leukemia7 studies
- Cancer (all types)6 studies
- COPD5 studies
- Breast Cancer5 studies
- Leukemia4 studies
- Parkinson's Disease4 studies
- Lung Cancer4 studies
- Cardiovascular Disease4 studies
- Cystic Fibrosis4 studies
- Non-Small Cell Lung Cancer4 studies
- Prostate Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.